ENTA 12.63 Enanta Pharmaceuticals, Inc.
| Range: | 8.08-17.8 | Vol Avg: | 164842 | Last Div: | 0 | Changes: | 0.35 |
| Beta: | 0.58 | Cap: | 0.27B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 21 2013 | Empoloyees: | 145 | ||
| CUSIP: | 29251M106 | CIK: | 0001177648 | ISIN: | US29251M1062 | Country: | US |
| CEO: | Dr. Jay R. Luly Ph.D. | Website: | https://www.enanta.com | ||||
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow